BVXV News and Press, BiondVax Pharmaceuticals Ltd. From 06/20/23

Biotechnology company BiondVax has entered into a collaboration with Max Planck Institute for Multidisciplinary Sciences (“MPG”) and the University Medical Center Göttingen (“UMG”) to develop innovative NanoAbs BiondVax enjoys an exclusive option for an exclusiv...

The European Alliance of Associations for Rheumatology has reported an influx in the prevalence of auto-inflammatory and autoimmune diseases. Autoimmune conditions are diseases that occur when the body’s immune system mistakes healthy tissues for harmful cells and attacks normal cells....

BiondVax (NASDAQ: BVXV) , a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, recently published Q1 2023 financial results and provided a business update. “...

In November 2022,  more than 100,000 Americans were on the organ transplant list eagerly awaiting an organ. But with the United States having just only approximately 20,000 organ donors , a large portion of people on the organ transplant list have to wait for months or even years. Still, ...

Immunotherapy is a relatively novel way of treating cancer. It entails boosting one’s immune system so it can locate and destroy cancer cells. This type of treatment is typically recommended for patients suffering from cases of advanced cancer, and it can be used to address conditions such...

2023-06-06 08:19:00 ET HTG Molecular Diagnostics ( HTGM ) -40% . Ucommune International ( UK ) -16% . EZGO Technologies EZGO -8% on $8.5M direct offering . Timber Pharmaceuticals ( TMBR ) -10% . Celestica CLS -8% on pricing secondary sto...

2023-06-05 13:14:14 ET U.S.-listed shares of BiondVax Pharmaceuticals ( NASDAQ: BVXV ) jumped as much as 32% on Monday on a license agreement to develop antibodies. BVXV stock was last up 6.3% to $1.82 in afternoon trade. The micro-cap biotech signed an ex...

2023-06-05 10:06:47 ET Gainers: Timber Pharmaceuticals ( TMBR ) +36% . Amedisys ( AMED ) +15% . Rockwell Medical ( RMTI ) +15% . Coeptis Therapeutics ( COEP ) +14% . BiondVax Pharmaceuticals ( BVXV ) +12% . Losers: Bellerophon ...

BiondVax Pharmaceuticals (NASDAQ: BVXV) , a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, has signed an exclusive worldwide license agreement. The agreement, w...

Broad-based collaboration with Max Planck and University Medical Center Gottingen yields attractive anti-IL-17 VHH antibodies (NanoAbs); includes exclusive worldwide license for all potential indications, beginning with psoriasis. BiondVax to lead development and commercialization of Nano...